Drugs / B1344
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07128797 | Jul 2025 → Jun 2026 overdue | NAFLD1, metabolic dysfunction-associated steatohepatitis | Tasly Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05655221 Comparator | Aug 2022 → Jul 2023 | metabolic dysfunction-associated steatohepatitis | Tasly Biopharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B1344 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07128797 ↗ |
| Modality | Protein / enzyme biologic | “pegylated conjugate of recombinant human mutated fibroblast growth factor 21” NCT05655221 ↗ |
| Route | Subcutaneous | “single subcutaneous (s.c.) injection” NCT05655221 ↗ |